© Reuters.
NEW YORK (Reuters) – A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson (NYSE:) of providing drug pricing tools to doctors to induce them to purchase drugs from the company.
The decision by the 2nd U.S. Circuit Court of Appeals in Manhattan restores claims by Adam Hart, a former McKesson business development executive.
If you’ve ever felt frustrated by slow-loading finance websites cluttered with ads and pop-ups, you’re not alone. StockAnalysis.com has quietly...
Janus Henderson Investors exists to help clients achieve their long-term financial goals. Formed in 2017 from the merger between Janus...
San Mateo, CA and Chicago, IL, Feb. 11, 2026 (GLOBE NEWSWIRE) — New data from both Circana and B-Stock reveals...
If you’re researching whether to join Round Sky as an affiliate or partner with them as a lender, you’ve likely...
One thing has been consistently true about the investment marketing business, at least for as long as I’ve been paying...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
